Exploring the efficacy of FAPI PET/CT in the diagnosis and treatment management of colorectal cancer: a comprehensive literature review and initial experience

[1]  Potential utility of [68Ga]DOTA-FAPI-04 as a broad-spectrum benign disease imaging agent-comparison with [18F]FDG and [99mTc]MDP. , 2023, European radiology.

[2]  Hua Wu,et al.  Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy , 2023, The Journal of Nuclear Medicine.

[3]  Reyhaneh Manafi-Farid,et al.  The Prognostic and therapeutic value and clinical implications of fibroblast activation protein-α as a novel biomarker in colorectal cancer , 2023, Cell Communication and Signaling.

[4]  M. Chorawala,et al.  The future of cancer immunotherapy: DNA vaccines leading the way , 2023, Medical Oncology.

[5]  Xue-juan Wang,et al.  Diagnostic value of [68Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET/CT , 2023, Frontiers in Oncology.

[6]  Yaming Li,et al.  FAPI PET/CT in Diagnostic and Treatment Management of Colorectal Cancer: Review of Current Research Status , 2023, Journal of clinical medicine.

[7]  J. Souglakos,et al.  Cancer-Associated Fibroblasts: The Origin, Biological Characteristics and Role in Cancer—A Glance on Colorectal Cancer , 2022, Cancers.

[8]  Yuedong Chen,et al.  Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG Uptake in Esophageal Cancer , 2022, Frontiers in Oncology.

[9]  Zuoquan Zhao,et al.  Rational Design and Pharmacomodulation of Protein-Binding Theranostic Radioligands for Targeting the Fibroblast Activation Protein. , 2022, Journal of medicinal chemistry.

[10]  P. Zhang,et al.  Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Yunchao Huang,et al.  FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century , 2022, Frontiers in Oncology.

[12]  W. Mesker,et al.  Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT , 2022, Clinical and Translational Oncology.

[13]  F. Giesel,et al.  Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging , 2022, British Journal of Cancer.

[14]  Jonathan T. Bliggenstorfer,et al.  Lymph node yield after rectal resection is a predictor of survival among patients with node-negative rectal adenocarcinoma. , 2022, Surgery.

[15]  P. Khong,et al.  Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics , 2022, Theranostics.

[16]  Jilin Li,et al.  Clinical Significance and Prognostic Value of the Maximum Standardized Uptake Value of 18F-Flurodeoxyglucose Positron Emission Tomography–Computed Tomography in Colorectal Cancer , 2021, Frontiers in Oncology.

[17]  J. Czernin,et al.  Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study , 2021, The Journal of Nuclear Medicine.

[18]  W. Cai,et al.  PET with a 68Ga-Labeled FAPI Dimer: Moving Toward Theranostics , 2021, The Journal of Nuclear Medicine.

[19]  F. Giesel,et al.  Radioligands Targeting Fibroblast Activation Protein (FAP) , 2021, Cancers.

[20]  H. Mohammadi,et al.  Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. , 2021, International immunopharmacology.

[21]  Chen Liang,et al.  Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.

[22]  Akira Saito,et al.  Organ Specificity and Heterogeneity of Cancer-Associated Fibroblasts in Colorectal Cancer , 2021, International journal of molecular sciences.

[23]  H. Cui,et al.  The Versatile Roles of Cancer-Associated Fibroblasts in Colorectal Cancer and Therapeutic Implications , 2021, Frontiers in Cell and Developmental Biology.

[24]  Mengxin Xu,et al.  Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy , 2021, The Journal of Nuclear Medicine.

[25]  P. Choyke,et al.  FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? , 2021, Cancers.

[26]  Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Zhide Guo,et al.  Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer , 2021, The Journal of Nuclear Medicine.

[28]  R. Kalluri,et al.  Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.

[29]  B. Song,et al.  Predictive Value of Metabolic Parameters Derived From 18F-FDG PET/CT for Microsatellite Instability in Patients With Colorectal Carcinoma , 2021, Frontiers in Immunology.

[30]  Mohcine Bennani Mechita,et al.  Colorectal Cancer: From Genetic Landscape to Targeted Therapy , 2021, Journal of oncology.

[31]  R. Baum,et al.  Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results , 2021, The Journal of Nuclear Medicine.

[32]  J. Debus,et al.  Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  N. Arlicot,et al.  Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review of in vitro and Preclinical Imaging Studies , 2021, Frontiers in Medicine.

[34]  Xiaodong Wang,et al.  Effects of molecular markers on the treatment decision and prognosis of colorectal cancer: a narrative review. , 2021, Journal of gastrointestinal oncology.

[35]  D. Jäger,et al.  68Ga-FAPI-PET/CT in patients with various gynecological malignancies , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  A. Chiti,et al.  State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  C. Gündoğan,et al.  68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT , 2021, Annals of Nuclear Medicine.

[38]  T. Sugai,et al.  Microenvironmental markers are correlated with lymph node metastasis in invasive submucosal colorectal cancer , 2021, Histopathology.

[39]  F. Fraioli,et al.  FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  U. Elboğa,et al.  Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. , 2021, European journal of radiology.

[41]  I. de Hingh,et al.  Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges , 2021, Frontiers in Oncology.

[42]  D. Schrag,et al.  Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. , 2021, JAMA.

[43]  J. Debus,et al.  Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer , 2021, Cancers.

[44]  M. van Egmond,et al.  Surgery for Colorectal Cancer: A Trigger for Liver Metastases Development? New Insights into the Underlying Mechanisms , 2021, Biomedicines.

[45]  Hua Wu,et al.  Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  M. Mahoney,et al.  Designing an exercise intervention for adult survivors of childhood cancers , 2021, BMC cancer.

[47]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[48]  R. Tothill,et al.  FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology? , 2020, The Journal of Nuclear Medicine.

[49]  Hua Wu,et al.  Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. , 2020, Radiology.

[50]  M. Yadav,et al.  Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  Shivan J. Mehta,et al.  NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[52]  J. Welsh,et al.  Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma , 2020, Journal for ImmunoTherapy of Cancer.

[53]  J. Stone,et al.  Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging , 2020, Annals of the Rheumatic Diseases.

[54]  L. Terracciano,et al.  High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes , 2020, Frontiers in Oncology.

[55]  L. Weiner,et al.  The role of fibroblast activation protein in health and malignancy , 2020, Cancer and Metastasis Reviews.

[56]  Hua Wu,et al.  Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  Fredrik Y Frejd,et al.  Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond , 2020, EJNMMI Radiopharmacy and Chemistry.

[58]  Wen Zhang,et al.  Fibroblast Activation Protein–Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT , 2020, The Journal of Nuclear Medicine.

[59]  E. Cukierman,et al.  Cancer Associated Fibroblast: Mediators of Tumorigenesis. , 2020, Matrix biology : journal of the International Society for Matrix Biology.

[60]  I. Badiola,et al.  Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases , 2020, Aging.

[61]  C. Langner,et al.  Pathology of Fibrosis in Crohn's Disease—Contribution to Understanding Its Pathogenesis , 2020, Frontiers in Medicine.

[62]  Hua Wu,et al.  Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  Zachary T. Rosenkrans,et al.  ImmunoPET: Concept, Design, and Applications. , 2020, Chemical reviews.

[64]  M. Keramati,et al.  Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. , 2020, Pathology, research and practice.

[65]  R. Beets-Tan,et al.  Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis , 2020, European Radiology.

[66]  J. Debus,et al.  The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience , 2020, The Journal of Nuclear Medicine.

[67]  J. Calais.  FAP: The Next Billion Dollar Nuclear Theranostics Target? , 2020, The Journal of Nuclear Medicine.

[68]  U. Haberkorn,et al.  Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients , 2019, The Journal of Nuclear Medicine.

[69]  Wolfgang A. Weber,et al.  Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine , 2019, The Journal of Nuclear Medicine.

[70]  Stephan G. Nekolla,et al.  Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04 , 2019, The Journal of Nuclear Medicine.

[71]  Hannah Sanford-Crane,et al.  Fibroblasts as Modulators of Local and Systemic Cancer Metabolism , 2019, Cancers.

[72]  H. Kauczor,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[73]  R. Tollenaar,et al.  Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer , 2019, BMC Cancer.

[74]  R. Vanna,et al.  Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy , 2019, International journal of molecular sciences.

[75]  H. Kim,et al.  Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer , 2018, Cancer Imaging.

[76]  D. Jäger,et al.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts , 2018, The Journal of Nuclear Medicine.

[77]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[78]  R. Boellaard,et al.  Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[79]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[80]  E. Puré,et al.  Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics , 2018, Oncogene.

[81]  Habib Zaidi,et al.  Dynamic whole-body PET imaging: principles, potentials and applications , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[82]  A. Kimmelman,et al.  Metabolic Interactions in the Tumor Microenvironment. , 2017, Trends in cell biology.

[83]  L. Påhlman,et al.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  Xinhua Wang,et al.  FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. , 2017, Biochemical and biophysical research communications.

[85]  O. De Wever,et al.  Fibroblast activation protein‐α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations , 2016, Molecular oncology.

[86]  W. Garrett,et al.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function , 2015, Cell reports.

[87]  M. Luyer,et al.  Peritoneal Cancer Patients Not Suitable for Cytoreductive Surgery and HIPEC During Explorative Surgery: Risk Factors, Treatment Options, and Prognosis , 2015, Annals of Surgical Oncology.

[88]  Dehai Che,et al.  Fibroblast Activation Protein Overexpression and Clinical Implications in Solid Tumors: A Meta-Analysis , 2015, PloS one.

[89]  D. Elias,et al.  Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study , 2015, Annals of Surgical Oncology.

[90]  A. Lambeir,et al.  Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). , 2014, Journal of medicinal chemistry.

[91]  A. Lambeir,et al.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. , 2013, ACS medicinal chemistry letters.

[92]  C. Eng,et al.  Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. , 2007, JAMA.

[93]  J. Guillem,et al.  The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer. , 2005, Journal of the American College of Surgeons.

[94]  P Schmidlin,et al.  Recurrence of colorectal tumors: PET evaluation. , 1989, Radiology.

[95]  R. Wahl,et al.  Monoclonal Antibody Radioimmunodetection of Human-derived Colon Cancer , 1982 .

[96]  Ebubekir Gündeş,et al.  Comparison of [ , 2022 .

[97]  Alper Aytekin,et al.  Comparison of , 2022 .